heat
shock
protein
molecular
chaperon
express
respons
stress
role
bind
protein
substrat
stabil
denatur
aggreg
condit
addit
function
stress
respons
multipl
respons
normal
growth
assist
fold
newli
synthes
subcellular
transport
protein
format
dissoci
degrad
unwant
thu
chaperon
broadli
shape
protein
homeostasi
control
protein
qualiti
control
turnov
normal
stress
consist
divers
activ
genet
biochem
studi
implic
rang
diseas
includ
cancer
neurodegener
allograft
reject
infect
review
provid
brief
review
structur
function
explor
emerg
opportun
challeng
drug
discoveri
member
famili
ubiquit
express
highli
conserv
exampl
major
escherichia
coli
term
dnak
approxim
ident
human
eukaryot
often
express
multipl
famili
member
major
isoform
found
cellular
compart
heat
shock
cognat
cytosol
nucleu
bip
endoplasm
reticulum
mitochondria
function
cytosol
isoform
thought
redund
transcript
highli
respons
stress
constitut
express
er
mitochondria
famili
member
thought
fulfil
specif
function
uniqu
substrat
bip
play
key
role
fold
qualiti
control
er
protein
involv
import
export
protein
mitochondria
purpos
review
often
use
gener
term
encompass
share
properti
famili
member
member
famili
ntermin
nucleotid
bind
domain
nbd
kda
ctermin
substratebind
domain
sbd
kda
connect
short
linker
figur
nbd
consist
two
subdomain
ii
divid
region
b
ia
iia
subdomain
interact
atp
nucleotidebind
cassett
relat
hexokinas
actin
glycerol
sbd
consist
subdomain
crystal
structur
suggest
substrat
peptid
bound
extend
conform
loop
subdomain
act
lid
substrat
thought
includ
linear
polypeptid
found
newli
synthes
protein
fold
expos
region
fulli
partial
fold
protein
exampl
known
interact
clathrin
compon
transcript
activ
complex
nuclear
hormon
receptor
mani
divers
substrat
allow
low
sequenc
select
sbd
bind
peptid
compos
nonpolar
amino
mani
function
appear
revolv
around
crosstalk
atpas
activ
nbd
substrat
bind
sbd
bind
tightli
atp
report
e
coli
dnak
bind
k
interdomain
alloster
mechan
atp
bind
increas
onand
offrat
peptid
bind
adjac
sbd
turn
nucleotid
hydrolysi
adp
close
lid
enhanc
affin
substrat
figur
likewis
interact
sbd
substrat
increas
rate
atp
hydrolysi
nbd
suggest
commun
two
domain
mechan
interdomain
commun
studi
extens
appear
involv
conserv
hydrophob
thu
drug
discoveri
viewpoint
allosteri
provid
multipl
opportun
chemic
intervent
includ
inhibit
atp
turnov
substrat
bind
even
block
interdomain
allosteri
isol
protein
atp
hydrolysi
rate
dnak
extrem
slow
vivo
properti
provid
opportun
regul
cochaperon
associ
control
nucleotid
turnov
exampl
j
protein
larg
group
cochaperon
stimul
atp
hydrolysi
figur
human
genom
least
differ
j
protein
gene
contain
conserv
amino
acid
j
domain
requir
bind
stimul
nmr
mutagenesi
crystallographi
studi
indic
least
one
bind
site
j
domain
nbd
proteinprotein
interact
j
domain
trigger
alloster
hotwir
nbd
enhanc
atp
turnov
approxim
thu
presenc
jprotein
releas
adp
becom
ratelimit
complet
atpas
cycl
distinct
class
cochaperon
nucleotid
exchang
factor
nef
catalyz
adp
releas
major
nef
famili
includ
grpelik
bag
famili
atyp
homolog
eg
nef
appear
bind
nbd
favor
adp
releas
class
use
differ
structur
mechan
achiev
togeth
jdomain
protein
nef
regul
atp
cycl
therefor
also
control
substrat
bind
addit
cochaperon
independ
bind
substrat
activ
potenti
influenc
substrat
select
thu
although
cochaperon
enzymat
activ
import
regulatori
factor
requir
mani
chaperon
function
heat
shock
protein
molecular
chaperon
express
respons
stress
role
bind
protein
substrat
stabil
denatur
aggreg
condit
addit
function
stress
respons
multipl
respons
normal
growth
assist
fold
newli
synthes
subcellular
transport
protein
format
dissoci
degrad
unwant
protein
thu
chaperon
broadli
shape
protein
homeostasi
control
protein
qualiti
control
turnov
normal
stress
consist
divers
activ
genet
biochem
studi
implic
rang
diseas
includ
cancer
neurodegener
allograft
reject
infect
review
provid
brief
review
structur
function
explor
emerg
opportun
challeng
drug
discoveri
member
famili
ubiquit
express
highli
conserv
exampl
major
escherichia
coli
term
dnak
approxim
ident
human
eukaryot
often
express
multipl
famili
member
major
isoform
found
cellular
compart
heat
shock
cognat
cytosol
nucleu
bip
endoplasm
reticulum
mitochondria
function
cytosol
isoform
thought
redund
transcript
highli
respons
stress
constitut
express
er
mitochondria
famili
member
thought
fulfil
specif
function
uniqu
substrat
bip
play
key
role
fold
qualiti
control
er
protein
involv
import
export
protein
mitochondria
purpos
review
often
use
gener
term
encompass
share
properti
famili
member
member
famili
ntermin
nucleotid
bind
domain
nbd
kda
ctermin
substratebind
domain
sbd
kda
connect
short
linker
figur
nbd
consist
two
subdomain
ii
divid
region
b
ia
iia
subdomain
interact
atp
nucleotidebind
cassett
relat
hexokinas
actin
glycerol
kinas
sbd
consist
subdomain
crystal
structur
suggest
substrat
peptid
bound
extend
conform
loop
subdomain
act
lid
substrat
thought
includ
linear
polypeptid
found
newli
synthes
protein
fold
expos
region
fulli
partial
fold
protein
exampl
known
interact
clathrin
compon
transcript
activ
complex
nuclear
hormon
receptor
mani
other
divers
substrat
allow
low
sequenc
select
sbd
bind
peptid
compos
nonpolar
amino
mani
function
appear
revolv
around
crosstalk
atpas
activ
nbd
substrat
bind
sbd
bind
tightli
atp
report
e
coli
dnak
bind
k
nm
interdomain
alloster
mechan
atp
bind
increas
onand
offrat
peptid
bind
adjac
sbd
turn
nucleotid
hydrolysi
adp
close
lid
enhanc
affin
substrat
figur
likewis
interact
sbd
substrat
increas
rate
atp
hydrolysi
nbd
suggest
commun
two
domain
twoway
mechan
interdomain
commun
studi
extens
appear
involv
conserv
hydrophob
thu
drug
discoveri
viewpoint
allosteri
provid
multipl
opportun
chemic
intervent
includ
inhibit
atp
turnov
substrat
bind
even
block
interdomain
allosteri
isol
protein
atp
hydrolysi
rate
dnak
extrem
slow
vivo
properti
provid
opportun
regul
cochaperon
associ
control
nucleotid
turnov
exampl
j
protein
larg
group
cochaperon
stimul
atp
hydrolysi
figur
human
genom
least
differ
j
protein
gene
contain
conserv
amino
acid
j
domain
requir
bind
stimul
nmr
mutagenesi
crystallographi
studi
indic
least
one
bind
site
j
domain
nbd
proteinprotein
interact
j
domain
trigger
alloster
hotwir
nbd
enhanc
atp
turnov
approxim
thu
presenc
jprotein
releas
adp
becom
ratelimit
complet
atpas
cycl
distinct
class
cochaperon
nucleotid
exchang
factor
nef
catalyz
adp
releas
major
nef
famili
includ
grpelik
bag
famili
atyp
homolog
eg
nef
appear
bind
nbd
favor
adp
releas
class
use
differ
structur
mechan
achiev
togeth
jdomain
protein
nef
regul
atp
cycl
therefor
also
control
substrat
bind
addit
cochaperon
independ
bind
substrat
activ
potenti
influenc
substrat
select
thu
although
cochaperon
enzymat
activ
import
regulatori
factor
requir
mani
chaperon
function
final
group
cochaperon
tetratricopeptid
repeat
tpr
contain
protein
bind
eevd
sequenc
extrem
cterminu
interestingli
evolutionarili
unrel
molecular
chaperon
also
contain
eevd
motif
allow
also
interact
tpr
domain
tpr
character
acid
motif
form
antiparallel
protein
tpr
domain
also
addit
domain
activ
thu
cochaperon
thought
recruit
uniqu
capabl
complex
exampl
hop
three
domain
three
tpr
motif
hop
prefer
bind
adpbound
form
via
specif
bind
way
hop
bridg
assist
substrat
transfer
chaperon
believ
promot
substrat
anoth
tprdomain
protein
chip
also
contain
ubox
domain
supervis
triag
thu
although
hop
chip
bind
via
tpr
domain
outcom
interact
diametr
oppos
hop
favor
fold
chip
favor
degrad
base
observ
mani
other
thought
competit
cochaperon
might
drive
combinatori
assembl
chaperon
complex
specif
function
togeth
featur
suggest
proteinprotein
contact
complex
may
potenti
drug
target
express
routin
associ
poor
prognosi
multipl
form
exampl
high
level
associ
advers
outcom
breast
endometri
oral
colorect
prostat
cancer
well
certain
moreov
transgen
overexpress
suffici
induc
cell
lymphoma
observ
import
induct
misregul
cancer
potenti
mediat
alter
activ
heat
shock
transcript
factor
cancer
cell
overexpress
thought
provid
surviv
advantag
abl
interact
multipl
compon
caspasedepend
independ
apoptot
pathway
figur
tabl
exampl
chaperon
report
regul
import
apoptot
mediat
similarli
express
block
tnfinduc
apoptosi
activ
transloc
bax
cleavag
interact
thought
direct
exampl
immunoprecipit
shown
interact
context
prevent
bax
transloc
block
oligomer
step
necessari
disrupt
mitochondri
influenc
multipl
step
cascad
like
exert
even
potent
antiapoptot
activ
act
individu
protein
similarli
also
found
block
caspaseindepend
signal
activ
cathepsin
exampl
knockdown
increas
cathepsin
b
releas
protect
lysosom
photoand
h
mediat
addit
effect
caspasedepend
independ
apoptot
pathway
also
play
role
senesc
effect
togeth
result
suggest
interact
multipl
partner
apoptosi
senesc
pathway
model
consist
known
substrat
promiscu
importantli
atpas
activ
nt
appear
requir
activ
action
jnk
aif
occur
independ
nucleotid
import
observ
mani
earli
inhibitor
target
atpas
activ
shrnamedi
knockdown
induc
apoptosi
slow
cell
prolifer
multipl
cancer
cell
unclear
whether
inhibitor
specif
function
nucleotid
turnov
mimic
favor
cellular
effect
regardless
studi
suggest
cancer
cell
becom
addict
chaperon
activ
multipl
parallel
signal
overexpress
also
document
provid
resist
chemotherapeut
agent
imatinib
etopisid
cisplatin
although
detail
mechan
resist
remain
elucid
recent
evid
suggest
reduc
activ
erk
jnk
pathway
may
respons
protect
effect
particularli
strike
respons
treatment
inhibitor
geldanamycin
like
atputil
molecular
chaperon
role
protein
howev
often
consid
special
chaperon
rel
restrict
set
cellular
substrat
among
key
antiapoptot
protein
includ
akt
inhibit
bind
atp
lead
proteasom
degrad
substrat
correspond
antiprolif
activ
context
discuss
treatment
inhibitor
also
found
induc
express
like
activ
discuss
compensatori
mechan
caus
resist
apoptosi
stabil
share
protein
substrat
togeth
observ
suggest
dual
therapi
might
benefici
hypothesi
strongli
support
observ
rnai
knockdown
enhanc
efficaci
one
import
role
assist
protein
fold
turnov
normal
cell
qualiti
control
system
prevent
accumul
toxic
misfold
protein
speci
howev
respons
mutagenesi
age
oxid
stress
misfold
often
occur
postmitot
cell
neuron
appear
particularli
sensit
effect
mani
neurodegen
disord
alzheim
parkinson
huntington
diseas
involv
aberr
accumul
misfold
misprocess
protein
genet
studi
routin
link
cochaperon
process
thu
emerg
potenti
drug
target
tabl
exampl
one
recent
studi
shown
directli
stabil
lysozom
play
key
role
niemannpick
diseas
discuss
two
model
inform
found
recent
review
polyglutamin
polyq
diseas
famili
least
nine
inherit
neurodegen
disord
includ
huntington
diseas
hd
spinocerebellar
ataxia
sca
spinal
bulbar
muscular
atrophi
sbma
caus
expans
trinucleotid
cag
repeat
diseas
expans
lead
format
abnorm
long
glutamin
tract
synthes
protein
polyq
expans
render
diseas
protein
prone
aggreg
extent
aggreg
correl
length
polyq
vitro
along
jdomain
cochaperon
partial
suppress
aggreg
polyqexpand
exon
huntingtin
htt
atpdepend
remodel
importantli
chaperon
activ
ad
lag
phase
aggreg
reaction
suggest
prefer
act
earli
prefibrillar
state
figur
similarli
yeast
model
overexpress
yeast
decreas
aggreg
htt
increas
sd
howev
relationship
appear
complex
cell
overexpress
show
littl
effect
htt
similar
theme
observ
anim
model
exampl
fli
model
mous
model
sbma
overexpress
suppress
neurodegen
signific
effect
observ
mous
model
hd
worth
note
clear
whether
polyq
aggreg
good
surrog
toxic
moreov
clear
effect
cell
viabil
alway
mediat
direct
effect
polyq
assembl
gener
buffer
prosurviv
despit
uncertainti
interest
note
sever
cochaperon
includ
jdomain
protein
chip
bag
dramat
effect
polyq
aggreg
format
either
concert
exampl
overexpress
yeast
jdomain
cochaperon
increas
solubl
wherea
relat
jdomain
cochaperon
split
larg
inclus
smaller
loci
tprdomain
cochaperon
chip
ubiquitin
htt
facilit
degrad
ubox
depend
manner
figur
overexpress
chip
also
significantli
rescu
neurodegen
symptom
anim
model
sbma
hd
chip
mice
exagger
diseas
progress
model
hd
role
chipmedi
protect
remain
establish
current
model
suggest
requir
chipmedi
togeth
observ
suggest
protect
polyq
toxic
might
requir
interplay
multipl
compon
complex
chaperon
cochaperon
inde
shown
chemic
stimul
heat
shock
respons
geldanamycin
allylamino
geldanamycin
geranylgeranylaceton
celastrol
upregul
multipl
chaperon
compon
rescu
neurodegen
symptom
cell
cultur
fli
mous
model
hd
alzheim
diseas
ad
common
neurodegen
diseas
patient
character
progress
memori
loss
accumul
senil
plaqu
sp
compos
neurofibrillari
tangl
nft
assembl
tau
current
model
suggest
selfassoci
tau
rich
oligom
lead
neuron
cell
death
figur
shown
play
import
role
cytotox
tau
exampl
block
earli
stage
aggreg
vitro
substoichiometr
figur
shown
alter
process
amyloid
precursor
protein
also
chaperon
protect
cytotox
via
inhibit
acceler
elimin
addit
effect
also
bind
tau
two
site
within
tubulinbind
repeat
region
requir
tau
selfassoci
find
suggest
might
compet
aggreg
consist
model
overexpress
reduc
aggreg
tau
mous
moreov
increas
level
promot
tau
bind
microtubul
reduc
level
hyperphosphoryl
similar
polyq
exampl
list
cochaperon
also
play
role
tau
process
exampl
chip
ubiquitin
phosphoryl
tau
overexpress
acceler
tau
degrad
reduc
format
insolubl
tau
rescu
tauinduc
cell
death
figur
tprdomain
cochaperon
also
impact
tau
aggreg
oppos
complex
bind
tau
inhibit
turnov
contrast
form
microtubuleteth
complex
captur
deliv
insolubl
phosphoryl
tau
proteasom
degrad
figur
like
ubiquitinindepend
togeth
result
illumin
complex
relationship
cochaperon
impact
ad
tauopathi
prokaryot
dnak
requir
surviv
bacteria
stress
condit
thermal
stress
challeng
heavi
metal
consist
activ
aureu
dnak
mutant
reduc
viabil
suscept
strikingli
mutat
increas
sensit
oxacillin
methicillin
normal
resist
aureu
strain
likewis
dnak
dnaj
mutat
e
coli
make
cell
suscept
chaperon
also
necessari
enterica
invad
epitheli
cell
l
monocytogen
surviv
thu
cochaperon
appear
potenti
drug
target
would
sensit
prokaryot
stress
provid
antibiot
host
respons
addit
role
bacteri
physiolog
also
import
host
immunolog
respons
cellcel
interact
exampl
mammalian
cell
infect
virul
form
choleraesui
level
correl
increas
induc
cell
heat
shock
protein
also
play
import
role
ikk
signal
endocyt
traffick
possibl
antigen
present
suggest
role
activ
regul
immun
cell
given
complex
role
diseas
immedi
appar
whether
good
therapeut
strategi
would
stimul
inhibit
otherwis
redirect
activ
chaperon
chemic
agent
exampl
would
stimul
atpas
activ
provid
protect
neurodegener
would
inhibit
sensit
cancer
cell
apoptosi
moreov
atpas
activ
ideal
target
anoth
function
eg
protein
fold
protein
traffick
etc
appropri
given
promiscu
interact
protein
possibl
influenc
process
individu
substrat
inhibitor
global
effect
although
answer
mani
import
question
remain
unknown
work
last
decad
provid
firstgener
interestingli
compound
belong
broad
rang
structur
class
distinct
nonoverlap
bind
site
surfac
observ
suggest
multipl
way
impact
function
modul
atpas
activ
contact
cochaperon
bind
misfold
substrat
importantli
earli
probe
also
begun
reveal
unexpect
aspect
biolog
thu
even
compound
directli
lead
approv
drug
start
defin
role
diseas
potenti
drug
target
follow
section
review
known
chemic
class
briefli
highlight
medicin
chemistri
effort
biolog
find
enabl
probe
umezawa
colleagu
report
identif
compound
antibiot
antitumor
activ
bacillu
character
activ
compound
polyamin
spergualin
figur
kondo
colleagu
carri
total
synthesi
compound
overal
howev
found
poor
stabil
vitro
vivo
led
synthesi
analogu
includ
aqueou
environ
ph
remov
labil
group
found
improv
stabil
rout
deriv
involv
formaldehydemedi
cycliz
spermidin
follow
coupl
free
amin
amino
acid
instal
fatti
acid
thu
approach
allow
readi
variat
amino
acid
ident
howev
antitumor
assay
leukemia
cell
glycin
lserin
deriv
retain
activ
wherea
even
conserv
replac
alanin
leucin
abolish
likewis
variat
polyamin
region
number
methyl
group
secondari
amin
decreas
taken
togeth
result
suggest
activ
profil
spergualin
analogu
surprisingli
narrow
despit
improv
stabil
compound
still
retain
rel
poor
bioavail
attempt
circumv
shortcom
seri
deriv
develop
amid
invert
chang
found
greatli
improv
molecul
stabil
follow
effort
hydroxyglycin
moieti
substitut
carbomoyl
group
produc
promis
deriv
tresperimu
lf
figur
howev
seri
minor
methyl
substitut
toler
posit
without
dramat
loss
exampl
r
methyl
group
append
near
terminu
compound
toler
opposit
stereochemistri
compound
appar
bind
reduc
immunosuppress
likewis
conserv
replac
methyl
ethyl
compound
greatli
reduc
activ
portion
molecul
equal
sensit
manipul
exampl
replac
guanidin
pyridin
reduc
activ
approxim
taken
togeth
structureact
studi
reveal
surprisingli
limit
rang
accept
modif
use
immobil
compound
deriv
found
bind
sever
protein
includ
base
mass
spectrometri
competit
studi
propos
bind
eevd
domain
chaperon
affin
interact
appear
impact
function
abl
increas
atpas
rate
approxim
although
chang
atp
turnov
rate
seem
minor
biolog
activ
compound
suggest
either
modest
chang
enzymat
activ
might
disproportion
impact
chaperon
function
b
atp
turnov
relev
vitro
assay
describ
activ
compound
chaperon
function
anoth
possibl
multipl
cellular
target
exampl
glycoprotein
suggest
potenti
although
compound
first
identifi
antiinfect
antitumor
agent
subsequ
identifi
potent
immunosuppress
molecular
mechan
activ
entir
clear
propos
block
traffick
antigen
present
two
known
cellular
role
regardless
decreas
incid
acut
reject
combin
cyclosporin
prolong
renal
allograft
immunolog
activ
appear
aris
effect
dendrit
activ
exampl
birck
colleagu
look
tcell
activ
patient
wegen
granulomatosi
found
patient
treat
lower
level
prolifer
marker
similarli
treatment
lead
decreas
mucos
injuri
reduc
mous
model
base
activ
explor
multipl
clinic
trial
allograft
reject
malign
cancer
wide
studi
indic
addit
detail
excel
review
briefli
poorli
bioavail
typic
deliv
iv
display
biexponenti
decay
alpha
halflif
minut
termin
halflif
approxim
metabol
believ
occur
part
amin
oxidas
seven
inact
metabolit
known
rodent
infus
mgkgday
day
lead
log
reduct
tumor
burden
leukemia
howev
phase
clinic
trial
monotherapi
advanc
malign
show
efficaci
mgkgday
similarli
phase
ii
trial
metastat
breast
cancer
patient
mg
day
iv
infus
day
also
show
efficaci
howev
trial
well
toler
low
toxic
observ
mild
neuromuscular
side
effect
grade
iii
toxic
activ
studi
immunolog
indic
promis
sinc
use
japan
acut
kidney
allograft
reject
advantag
compound
unlik
cyclosporin
use
hr
initi
reject
therefor
revers
ongo
organ
reject
anim
model
human
exampl
patient
undergo
acut
renal
allograft
reject
one
studi
show
revers
reject
even
monotherapi
importantli
p
substrat
use
cyclosporin
steroid
fact
studi
kidney
liver
allograft
reject
western
europ
reveal
revers
combin
bolu
addit
exampl
mani
pilot
clinic
studi
japan
us
report
gener
document
good
toler
low
toxic
efficaci
transplant
model
use
success
clinic
mechan
exert
effect
fulli
understood
exampl
specif
compound
specif
bind
eevd
control
chaperon
function
seemingli
minor
chang
atpas
rate
lead
directli
robust
cellular
effect
bind
import
activ
clearli
addit
structur
mechanist
experi
need
given
promis
biolog
activ
polyamin
brodski
colleagu
search
development
therapeut
databas
nation
cancer
institut
relat
compound
effort
yield
nsc
inhibit
atpas
activ
partial
block
chaperonemedi
protein
transloc
figur
howev
unlik
compound
mild
atpas
stimul
specif
inhibit
atpas
activ
presenc
jdomain
result
interest
although
origin
identifi
spergualinlik
analogu
might
oper
differ
mechan
follow
success
identif
brodski
colleagu
search
scaffold
abl
alter
atpas
activ
guid
structur
similar
focus
seri
function
dihydropyrimidin
figur
rout
compound
leverag
consecut
biginelli
ugi
multicompon
reaction
yield
divers
atpas
assay
sever
compound
seri
shown
inhibit
atp
hydrolysi
eg
compound
other
enhanc
activ
eg
compound
moreov
activ
compound
depend
presenc
jdomain
cochaperon
similar
seen
exampl
compound
effect
atp
hydrolysi
gave
reduct
ad
combin
jdomain
approxim
compound
test
experi
accordingli
quantit
sar
readili
appar
explor
seri
seventeen
addit
dihydropyrimidin
synthes
ugideriv
peptoid
portion
replac
proteaseresist
betapeptid
activ
deriv
test
atpas
activ
two
either
dnak
complex
jdomain
cochaperon
result
studi
suggest
hydrophob
substitut
near
dihydropyrimidin
core
figur
may
import
activ
exampl
compound
phenyl
substitut
region
chang
atp
turnov
interestingli
inhibitor
atpas
activ
stimul
consist
gener
observ
compound
class
either
type
activ
jdomain
present
also
stimul
bovin
e
coli
dnak
suggest
highli
homolog
protein
might
independ
target
despit
effort
potenc
compound
weak
ec
valu
make
challeng
interpret
sar
confirm
select
cell
part
challeng
recent
compound
test
small
number
high
throughput
assay
atpas
activ
avail
improv
capac
chang
et
al
convert
malachit
green
assay
highthroughput
platform
importantli
assay
employ
purifi
dnak
cochaperon
dnaj
grpe
boost
signal
provid
physiolog
turnov
advanc
allow
screen
collect
dihydropyrimidin
effort
sever
promis
deriv
block
dnak
activ
identifi
complement
approach
medium
throughput
luciferaserefold
assay
develop
assay
denatur
firefli
luciferas
dilut
presenc
threecompon
chaperon
complex
refold
monitor
recov
luminesc
member
dihydropyrimidin
collect
screen
format
best
compound
ec
valu
around
interestingli
obviou
structur
similar
activ
compound
atpas
assay
luciferasefold
assay
even
though
dihydropyrimidin
identifi
date
weak
activ
select
remain
establish
firstgener
compound
employ
varieti
biolog
system
importantli
studi
provid
unexpect
insight
function
diseas
model
one
exampl
stimulatori
dihydropyrimidin
found
enhanc
inhibit
convers
weak
inhibitor
atpas
activ
led
suppress
suggest
atp
hydrolysi
rate
chaperon
might
impact
antiaggreg
activ
vitro
test
model
cell
jinwal
et
al
use
inhibitor
activ
atpas
activ
model
tau
surprisingli
found
stimul
includ
led
dramat
accumul
tau
inhibitor
opposit
effect
inhibitor
reduc
tau
level
via
rapid
ubiquitin
ec
valu
importantli
overexpress
promot
activ
inhibitor
lower
ec
valu
consist
chaperon
import
cellular
target
final
intracrani
inject
found
reduc
tau
transgen
mice
suggest
inhibit
atpas
activ
might
viabl
strategi
reduc
accumul
misfold
tau
addit
studi
protein
misfold
aggreg
dihydropyrimidin
also
employ
explor
potenti
target
cancer
exampl
compound
found
antiprolif
activ
activ
appear
mediat
abil
dihydropyrimidin
interrupt
stimul
jprotein
cochaperon
gi
valu
seri
peptoidmodifi
dihydropyrimidin
tend
correl
activ
jstimul
atpas
moreov
best
compound
nearli
deriv
test
promis
gi
valu
approxim
cell
suggest
possibl
inhibit
alon
suffici
induc
apoptosi
explor
potenti
mechan
anticanc
activ
effect
activ
inhibitor
stabil
prosurviv
target
akt
explor
studi
found
activ
promot
akt
stabil
inhibitor
promot
akt
degrad
subsequ
cell
death
panel
cancer
cell
mechan
similar
propos
inhibitor
name
select
destabil
chaperon
substrat
lead
often
cooper
yet
entir
clear
role
might
play
respons
inhibitor
work
need
understand
molecular
mechan
howev
collect
find
across
multipl
model
protein
misfold
apoptosi
begun
reveal
potenti
avenu
toward
therapeut
intervent
sulfogalactosyl
ceramid
sulfogalactoglycerolipid
two
sulfoglycolipid
found
bind
mamelak
lingwood
identifi
put
bind
site
nbd
delet
analysi
sitedirect
mutagenesi
specif
mutat
two
residu
nbd
arg
phe
led
reduc
bind
shown
aglycon
portion
determin
whether
molecul
bind
bacteri
eukaryot
eukaryot
bound
sg
cer
sg
cer
sg
oh
cer
dnak
preferenti
bound
sg
cer
sg
oh
cer
substitut
aglycon
manipul
sulfat
phosphoryl
pattern
sugar
ablat
bind
demonstr
narrow
toler
full
sar
analysi
class
molecul
await
expand
librari
synthesi
addit
structur
studi
howev
earli
studi
reveal
substitut
acyl
chain
adamantyl
group
improv
affin
figur
specif
adasgc
found
ic
valu
interestingli
noncompetit
inhibitor
atpas
activ
molecular
mechan
inhibit
entir
clear
cell
increas
protein
level
mutant
cystic
fibrosi
transmembran
receptor
cftr
prone
misfold
degrad
erassoci
degrad
erad
thu
find
suggest
inhibit
atpas
activ
might
suppress
erad
pathway
normal
act
reduc
level
mutat
cftr
moreov
activ
found
depend
action
jdomain
contain
cochaperon
consist
complex
cellular
target
result
might
import
implic
use
drug
target
cystic
fibrosi
misfold
diseas
despit
insight
bind
site
glycolipid
loos
defin
select
yet
firmli
establish
anoth
exampl
fatti
acidlik
deriv
inhibit
function
acyl
benzamid
famili
class
compound
aros
work
schienefish
group
target
cistran
aminopeptidyl
isomeras
apias
activ
dnak
effort
identifi
potenti
antibiot
dnak
shown
catalyz
isomeras
activ
poorli
understood
mechan
effort
target
activ
small
molecul
yield
acyl
benzamid
ic
valu
low
found
length
fatti
acid
chain
import
determin
molecul
activ
figur
exampl
short
acyl
chain
gave
compound
poor
activ
apias
bacteri
growth
assay
increas
length
chain
tend
enhanc
potenc
compound
ic
apias
assay
mic
e
coli
ic
mic
howev
increas
fatti
acid
chainlength
also
enhanc
undesir
erythrocyt
hemolyt
activ
hemolyt
activ
could
partial
avoid
instal
unsatur
fatti
acid
exampl
compound
ci
alken
ec
hemolyt
assay
retain
activ
apias
bacteri
growth
substitut
amino
acid
portion
figur
alter
mic
valu
less
predict
effect
vitro
exampl
dramat
substitut
isoleucin
glutamin
phenylalanin
caus
modest
chang
apias
inhibit
increas
mic
approxim
togeth
find
suggest
vitro
activ
assay
proscrib
might
best
reflect
key
mechanist
role
play
chaperon
bacteria
reoccur
theme
field
role
measur
function
eg
atpas
apias
refold
etc
control
biolog
vivo
remain
uncertain
despit
discrep
mic
best
acyl
benzylamid
approxim
lower
ampicillin
suggest
compound
deriv
may
use
howev
import
note
select
formal
establish
offtarget
effect
compound
remain
unexplor
mention
dnak
consid
potenti
target
antibacteri
model
recent
test
pharmacolog
agent
exampl
seri
amino
acid
prolinerich
peptid
includ
drosocin
pyrrhocoricin
apidaecin
tabl
describ
bind
dnak
anoth
prokaryot
chaperon
groel
kill
suscept
bacteria
without
impact
mammalian
pyrrhocoricin
inhibit
atpas
activ
e
coli
dnak
bind
sbd
k
interact
thought
keep
lid
domain
close
posit
prevent
substrat
releas
model
support
comput
simul
mutagenesi
studi
identifi
sbd
residu
key
target
dnak
interestingli
pyrrhocoricin
bind
aureu
suggest
potenti
differ
gramposit
strain
effort
optim
pharmacokinet
antibacteri
activ
peptid
sever
analogu
repres
combin
peptid
sequenc
gener
deriv
grpdkprpylprprpprpvrl
activ
also
improv
serum
stabil
importantli
compound
activ
e
coli
resist
strain
enterobactericea
sp
mic
approxim
time
better
ciprofloxacin
moreov
toxic
eukaryot
cell
concentr
mgml
cudic
et
al
recent
gener
dimer
pyrrhocoricin
effort
improv
stabil
potenc
compound
increas
serum
stabil
compar
pyrrhocoricin
activ
isol
normal
resist
tetracyclin
compound
advanc
clinic
shown
target
dnak
may
viabl
antibacteri
strategi
given
atpas
activ
appear
one
central
determin
chaperon
function
compound
competit
bind
atp
might
expect
potent
activ
hypothesi
aris
part
analog
atp
competit
compound
geldanamycin
deriv
induc
degrad
substrat
recent
williamson
et
al
publish
first
compound
use
test
import
hypothesi
use
fluoresc
polar
assay
screen
adenosin
deriv
identifi
adenosin
affin
atpbind
site
activ
ic
figur
intend
bind
orient
confirm
cocryst
structur
group
substitut
retain
activ
ic
improv
toxic
profil
subsequ
modif
optim
residu
figur
substitut
group
yield
tight
bind
compound
ic
valu
importantli
also
activ
hct
colon
carcinoma
cell
gi
reduc
level
substrat
sensit
recent
compound
class
also
found
synergi
inhibitor
might
expect
base
share
function
chaperon
togeth
studi
repres
import
step
toward
submicromolar
affin
structureguid
design
inhibitor
celliti
et
al
recent
use
nmr
spectroscopi
identifi
compound
bind
specif
explor
proton
aliphat
region
h
nmr
spectra
e
coli
dnak
sbd
residu
effort
find
scaffold
interact
domain
effort
yield
pocket
near
form
groov
import
alloster
commun
sbd
nbd
compound
bound
site
princip
bind
confirm
isotherm
titrat
calorimetri
itc
k
valu
around
base
result
fifteen
deriv
either
thiophen
furan
core
varieti
hydrophob
group
append
synthes
figur
ad
bulk
substitu
seem
improv
affin
effort
yield
indolesubstitut
bound
k
final
member
seri
compound
found
inhibit
growth
e
coli
yersinia
pseudotuberculosi
mic
valu
approxim
depend
strain
growth
temperatur
best
compound
furan
mic
less
pseudotuberculosi
interestingli
potent
inhibitor
microbi
growth
compound
highest
affin
dnak
determin
itc
suggest
complex
relationship
bind
vivo
potenc
recent
leu
colleagu
report
identif
compound
bind
figur
compound
also
known
shown
select
toxic
cancer
cell
line
propos
effect
mechan
action
clear
biotinconjug
pe
reveal
bip
target
delet
analysi
restrict
bind
site
use
immunoprecipit
author
character
effect
assembl
chaperon
complex
differ
cell
line
hypothes
would
alter
cochaperon
associ
therebi
alter
chaperon
function
studi
reveal
prevent
interact
bag
protein
depend
cell
type
moreov
block
associ
consist
abil
kill
cancer
cell
block
caspas
activ
final
appear
interrupt
interact
import
protein
chaperonemedi
autophagi
consist
idea
longliv
protein
degrad
reduc
rate
respons
compound
caus
build
procathespin
l
indic
autophagi
lysosom
enzym
process
impair
togeth
studi
suggest
chang
interact
cochaperon
partner
activ
impact
substrat
fate
moreov
rel
simpl
structur
seem
like
addit
synthet
studi
might
improv
activ
potenti
select
effort
like
benefit
improv
structur
analysi
biophys
studi
mechan
chang
complex
assembl
rhodacyanin
figur
report
bind
pulldown
specif
delet
analysi
reveal
bind
near
atpbind
site
nbd
howev
cellular
select
isoform
like
driven
part
cation
charact
cation
compound
known
accumul
across
mitochondri
proton
gradient
rapidli
divid
cancer
cell
earli
experi
found
inhibit
prolifer
multipl
human
cancer
cell
line
includ
colon
bladder
breast
carcinoma
cell
ic
valu
rang
toxic
normal
kidney
base
find
preclin
evalu
rat
reveal
low
toxic
mgkgday
primarili
renal
impair
dose
mous
xenograft
studi
continu
infus
requir
antitumor
base
preclin
find
phase
clinic
trial
solid
tumor
perform
use
daili
infus
carri
five
time
three
week
mgm
subset
patient
renal
toxic
seen
major
toxic
importantli
pharmacokinet
measur
fail
detect
one
micromolar
serum
suggest
therapeut
dose
achiev
consist
littl
improv
diseas
seen
patient
achiev
stabl
diseas
howev
studi
suggest
target
mitochondri
might
viabl
strategi
toxic
pharmacokinet
scaffold
could
improv
addit
detail
select
activ
compound
might
guid
effort
includ
comprehens
list
compound
activ
sever
molecul
either
recent
discov
older
one
await
studi
exampl
steroidlik
molecul
tubocapsenolid
found
oxid
thiol
caus
also
sever
report
suggest
epigallocatechin
gallat
inhibit
includ
bip
allow
initi
apoptot
likewis
flavonoid
myricetin
inhibit
atpas
activ
reduc
tau
level
anticanc
activ
multipl
clearli
note
polyphenol
notori
promiscu
howev
uncov
bind
site
mechan
might
reveal
new
druggabl
site
opportun
structureguid
design
recent
imidazol
report
william
et
al
induc
apoptosi
interact
haney
et
al
report
ugideriv
peptoid
modul
atpas
activ
bind
final
peptid
deriv
shown
inhibit
interact
inhibit
prolifer
breast
cancer
last
result
emphas
import
contribut
cochaperon
guid
activ
complex
much
work
remain
optim
compound
establish
select
provid
illustr
wide
divers
structur
found
interact
chaperon
critic
molecular
chaperon
cell
surviv
signal
protein
homeostasi
gather
signific
attent
potenti
emerg
drug
target
genet
studi
eg
knockdown
overexpress
clearli
demonstr
cochaperon
involv
cancer
neurodegener
diseas
next
step
determin
variou
function
pharmacolog
manipul
whether
outcom
intervent
well
toler
first
glanc
target
core
mediat
protein
homeostasi
might
consid
challeng
given
widespread
cellular
role
ampl
opportun
toxic
part
enthusiasm
drug
target
base
success
program
target
core
molecular
chaperon
mention
inhibitor
specif
destabil
prosurviv
signal
protein
cancer
cell
result
earli
anticanc
trial
appear
promis
howev
field
inhibitor
less
matur
mani
import
question
remain
consid
equal
good
drug
target
review
discuss
earli
effort
identifi
inhibitor
highlight
biolog
find
enabl
reagent
howev
mani
question
remain
consid
fulli
valid
drug
target
exampl
multipl
assay
use
measur
activ
vitro
eg
atpas
activ
apias
activ
substrat
fold
antiapoptot
signal
etc
relationship
measur
function
chaperon
role
vivo
remain
unclear
addit
gener
lack
select
inform
firstgener
compound
thu
seem
like
least
compound
enact
cellular
activ
multipl
pathway
preclud
definit
statement
drug
target
clearli
one
major
problem
field
consensu
assay
studi
lack
analog
inhibitor
often
test
batteri
standard
assay
includ
measur
chaperon
bind
vitro
abil
reduc
level
substrat
akt
raf
futur
effort
benefit
similar
routin
util
vitro
bind
assay
b
examin
cellular
effect
put
substrat
tau
akt
c
studi
effect
overexpress
compound
efficaci
last
point
particularli
import
opinion
interpret
pulldown
studi
often
use
document
bind
cell
complic
hydrophob
promiscu
chaperon
abund
thu
overexpress
studi
may
provid
readili
interpret
altern
anoth
interest
approach
transcript
profil
previous
use
identifi
novel
inhibitor
final
greater
emphasi
structur
studi
seem
warrant
permit
insight
bind
site
put
inhibitor
field
extens
crystallographi
studi
yield
import
molecular
detail
bind
site
field
inhibitor
matur
increas
util
structur
analysi
broader
assay
profil
ultim
acceler
discoveri
interest
note
wide
varieti
chemic
scaffold
eg
polyamin
fatti
acid
sulfoglycolipid
peptid
adenosin
etc
identifi
affin
although
scaffold
like
promiscu
observ
still
suggest
harbor
unusu
number
potenti
drugbind
site
accommod
varieti
chemic
scaffold
site
might
includ
deep
pocket
found
atpbind
cleft
substratebind
region
shallow
surfac
involv
allosteri
proteinprotein
interact
cochaperon
although
compound
discuss
herein
explor
suffici
molecular
detail
earli
find
suggest
multipl
way
impact
function
exampl
compound
peptid
seem
interrupt
contact
cochaperon
directli
compet
nucleotid
bind
one
interest
aspect
biolog
remain
fulli
leverag
abil
chaperon
form
multiprotein
complex
discuss
interact
multipl
class
cochaperon
partner
known
shape
activ
thu
specif
target
interact
regulatori
partner
would
expect
control
specif
chaperon
approach
might
expect
limit
toxic
reduc
global
impair
protein
homeostasi
move
forward
propos
emphasi
structur
biolog
cochaperon
combin
deeper
insight
factor
shape
proteom
requir
ration
leverag
effect
drug
target
summari
genet
biochem
studi
support
interest
potenti
drug
target
remark
wide
rang
diseas
earli
studi
inhibitor
support
gener
conclus
howev
field
inhibitor
clearli
infanc
extens
work
remain
clear
chaperon
best
exploit
alzheim
diseas
work
support
grant
jeg
cge
support
predoctor
fellowship
author
thank
erik
zuiderweg
member
gestwicki
laboratori
help
convers
idea
thought
promot
surviv
block
apoptosi
interact
multipl
step
pathway
substrat
role
appear
stabil
substrat
appear
mediat
degrad
substrat
regulatori
mechan
govern
activ
known
see
main
text
tabl
refer
link
multipl
step
protein
misfold
aggreg
pathway
includ
prevent
misfold
block
earli
stage
aggreg
mediat
degrad
misfold
intermedi
coupl
ubiquitinproteasom
system
cochaperon
chip
link
clearanc
misfold
protein
system
includ
yeast
prion
activ
requir
fibril
format
simplic
schemat
encompass
broad
aspect
misfold
pathway
amyloid
beta
polyglutamin
tau
although
import
differ
like
exist
see
main
text
tabl
refer
role
apoptot
signal
ref
pathway
inhibit
tnf
activ
bid
pathway
inhibit
recruit
apoptosom
bind
prevent
format
activ
apoptosom
inhibit
proteasom
degrad
protein
dnak
necessari
replic
brucella
sui
macrophag
protect
macrophag
cell
death
infect
salmonella
choleraesui
immun
function
involv
mhc
class
ii
antigen
present
endocyt
matur
cell
entri
exit
